Nomograms for clinically localized prostate cancer. Part II: Radiation therapy

Seminars in Urologic Oncology

Volumn 20, Issue 2, 2002, Pages 131-139

  Potters, Louis ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; Modeling; Nomogram; Prostate neoplasm; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BEAM THERAPY; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CONTROLLED STUDY; DEVICE; EVALUATION; HIGH RISK POPULATION; HUMAN; MALE; METHODOLOGY; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0036094532     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.32494     Document Type: Article

References (40)

1. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate
2. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis
3. Long-term results of retropubic permanent 125 iodine implantation of the prostate for clinically localized prostatic cancer
4. A dose-response study for 1-125 prostate implants
5. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy
6. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
7. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer
8. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
9. A prospective survey of radiotherapy in Sweden
10. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
11. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era
12. Risk profiles to predict PSA relapse-free survival for patients undergoing permanent prostate brachytherapy
13. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy
14. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
15. Dose selection for prostate cancer patients based on dose comparison and dose response studies
16. An enhanced prognostic system for clinically localized carcinoma of the prostate
17. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer
18. Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies
19. Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate
20. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials
21. Consensus statement: Guidelines for PSA following radiation therapy
22. The definition of biochemical failure in patients treated with definitive radiotherapy
23. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
24. Definitions of biochemical failure in prostate cancer following radiation therapy
25. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer
26. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
27. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
28. A catalog of prostate cancer nomograms
29. A pretreatment nomogram for predicting recurrence-free survival following permanent prostate brachytherapy in cancer
30. Regression models and life tables
31. Regression modeling strategies for improved prognostic prediction
32. Experiments to determine whether recursive partitioning (CART) or an artificial neural network overcomes theoretical limitations of Cox proportional hazards regression
33. Neural networks as statistical methods in survival analysis
34. Regression trees for censored data biometrics
35. Polychotomous regression
36. Multivariate prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
37. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer
38. A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate cancer